Pulse Biosciences appoints Kevin Danahy as Chief Commercial Officer, effective Feb 14

PULSE BIOSCIENCES, INC.

Kevin Danahy named CCO; receives $395,000 base salary, 50% target bonus.
Granted 300,000 stock options at $6.41/share (Feb 14 closing price), 4-year vesting.
Danahy has 20+ years in medtech; previously President at Solmetex, VP at Zimmer Biomet.
Appointment is an inducement award under Nasdaq Rule 5635(c)(4).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kevin Danahy

Chief Commercial Officer

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2022-02-14
Filed: February 15, 2022, 6:59 PM ET

On February 15, 2022, Pulse Biosciences, Inc. announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer, effective February 14, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On February 15, 2022, Pulse Biosciences, Inc. announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer, effective February 14, 2022.

View on SEC.gov

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001625101-22-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.